Cullen Frost Bankers Inc. Has $7.85 Million Stock Holdings in Kenvue Inc. $KVUE

Cullen Frost Bankers Inc. increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 7.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 374,907 shares of the company’s stock after acquiring an additional 27,118 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Kenvue were worth $7,847,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Kenvue by 4.9% during the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after acquiring an additional 10,600,682 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Kenvue by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after acquiring an additional 633,461 shares during the period. Boston Partners lifted its stake in shares of Kenvue by 7.4% during the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock valued at $606,920,000 after acquiring an additional 1,750,490 shares during the period. JPMorgan Chase & Co. lifted its stake in Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after buying an additional 2,597,920 shares during the period. Finally, American Century Companies Inc. lifted its stake in Kenvue by 15.7% in the first quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock valued at $523,456,000 after buying an additional 2,961,716 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 1.8%

NYSE KVUE opened at $15.20 on Thursday. The firm has a market cap of $29.16 billion, a P/E ratio of 20.53, a P/E/G ratio of 2.15 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The stock’s 50-day moving average is $18.15 and its 200-day moving average is $20.89. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue’s revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. Kenvue’s dividend payout ratio is 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. UBS Group cut their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Citigroup cut their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Royal Bank Of Canada cut their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Evercore ISI cut their target price on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a research note on Tuesday, September 23rd. Finally, Zacks Research raised Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $21.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.